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Response to cladribine in patient with systemic mastocytosis
Primena kladribina u lečenju bolesnika sa sistemskom mastocitozom
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Abstract
Introduction. Systemic mastocytosis is a heterogeneous group
of hematological disorders characterized by accumulation of
mast cells in different organs. Case report. A 41-year-old
woman presented with a three-year history of fatigue, occa-
sional diarrhea, mild fever, skin rash and splenomegaly. Labo-
ratory results showed severe anemia and thrombocytopenia.
Cytological and histological investigation of bone marrow
showed a marked increase of mast cells infiltration with fol-
lowing  immunophenotype: CD117+, CD68+, CD34-, MPO-,
CD15-. She was treated with cladribine 0.15 mg/kg body
weight from day 1 to day 5, a total of six cycles, and achieved a
good partial response, transfusion independency and  normali-
zation of spleen size. Although the patient responded to the
treatment, the relapse with splenomegaly and bicytopenia was
observed after 10 months. Conclusion. Cladribine therapy was
efficient in the patient' with systemic mastocytosis but the re-
sponse was transient, so there is the need to search for new
therapeutic options and more effective strategies in the treat-
ment of patients with aggressive mast cell disorders.
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Apstrakt
Uvod. Sistemska mastocitoza ubraja se u heterogenu grupu
hematoloških oboljenja, a karakteriše je nagomilavanje mast će-
lija u različitim organima. Prikaz bolesnika. Prikazana je bole-
snica, stara 41 godinu, koja je u poslednje tri godine imala sim-
ptome malaksalosti, povremene prolive, povišenu temperaturu,
osip po koži i splenomegaliju. Laboratorijski nalazi pokazali su
tešku anemiju i trombocitopeniju. Citološko i histološko ispiti-
vanje kostne srži pokazalo je izraženu infiltraciju mast ćelijama
sa imunofenotipom: CD117+, CD68+, CD34-, MPO-, CD15-
. Bolesnica je lečena kladribinom u dozi od 0,15 mg/kg telesne
mase, od prvog do petog dana, ukupno šest ciklusa, i postignut
je dobar parcijalni odgovor. Bolesnica nije zahtevala transfuzije
i veličina slezine se normalizovala. Iako je bolesnica povoljno
reagovala na primenjenu terapiju, nakon 10 meseci došlo je do
relapsa sa splenomegalijom i bicitopenijom. Zaključak.  Te-
rapija kladribinom je efikasna kod bolesnika sa sistemskom ma-
stocitozom, ali odgovor na lečenje je prolazan. Potrebno je is-
traživanje novih terapijskih agenasa i efikasnijih strategija u le-
čenju bolesnika sa agresivnim oblikom mastocitoze.
Ključne reči:
mastocitoza; citodijagnostika; kladribin; remisija,
indukcija; recidiv.
Introduction
Systemic mastocytosis (SM) is a clonal, extremely rare
disorder characterized by abnormal mast cell proliferation in
different organs, including bone marrow, skin, gastrointesti-
nal tract, liver, spleen and lymph nodes 
1. After skin, bone
marrow is the second most frequently involved organ, and its
infiltration by mast cells can lead to bone pain, pancytopenia
and pathologic fractures. The diagnosis of mastocytosis is
based on histological and immunohistochemical examination
of skin or bone marrow biopsy specimens 
2. Recommended
therapy for aggressive forms of SM consists of cytoreductive
agents and interferon-alpha (IFN-alpha) 
3.
Case report
A 40 year-old Caucasian woman presented with a two-
year history of fatigue, occasional diarrhea, mild fever and
rash. Physical examination and laboratory investigation re-
vealed maculopapular rash (Figure 1), mild splenomegaly,
with mild anemia (hemoglobin 103 g/L) and thrombocytope-
nia 129 × 10
9/L. Skin biopsy showed mastocyte infiltration
in the derm, and the diagnosis of cutaneous mastocytosis was
established. The patient was treated with symptomatic ther-
apy – histamine H1 and H2 receptor blockers. A year later
the patient was admitted to the hospital with severe fatigue,
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with disseminated itching rash, splenomegaly 5 cm below
the left costal margin. Ultrasonography and computed to-
mography (CT) scan showed splenomegaly 19 cm. Gastro-
duodenoscopy showed friable duodenal mucosa with multiple
erosions. Laboratory data revealed severe anemia with hemo-
globin concentration of 59 g/L, thrombocytopenia 18 × 10
9/L,
white cell blood count 5.l × 10
9/L (differential leukocyte for-
mula: myelocytes 1%, bands 3%, segmented 29%, eosinophils
3%, lymphocytes 51%, monocytes 13%, erythroblasts 21/100).
Erythrocyte sedimentation rate was elevated (134 mm/h). Co-
agulation parameters and serum immunoglobulin concentra-
tion (IgG 10.6 g/L; IgA 1.9 g/L; IgM 1.51 g/L) were normal.
Serum C-reactive protein 11.34 g/L (normal range 0–5 g/L)
and β2 microglobulin level 2.45 mg/L (normal range 0.70–1.80
mg/L) were elevated. The level of serum histamine 0.79 µmoL
(normal range 0.36–0.66 µmoL) and lactate dehydrogenase –
LDH (786 U/L) were increased. Serum ferritin was elevated,
743.0 µg/L (normal range 5.00–170.00 µ/L). Cytological in-
vestigation of bone marrow revealed a marked increase of
mast cells. A trephine biopsy showed infiltration of bone mar-
row by monomorphic, spindle shaped mast cells, and moder-
ate fibrosis of the bone marrow (Figure 2). These cells were
PAS negative. Their immunophenotype was c-kit/CD117+,
CD68+, CD34-, MPO-, CD15-, which is consistent with mast
cells. Cytogenetic analysis revealed normal female karyotype
46, XX. Cultures of hematopoietic progenitor cells showed
the increased number of CFU-GM colonies (colony-foming
unit granulocyte macrophage), spontaneous growth of BFU-
E (burst forming unit erythroid) and increased number of
erythropoietin stimulated BFU-E, comparing to the control
and the absence of CFU-MK (megakaryocyte progenitors).
Skeletal radiography did not show abnormalities on the
bones. Clinical presentation and laboratory findings were
consistent with the diagnosis of systemic mastocytosis. The
patient was treated with cladribine 0.15 mg/kg body weight
from day 1 to day 5, a total of six cycles. The cycles were re-
peated after 4 weeks. The response was assessed according
to the proposed criteria by Valent et al. 
4. The patient
achieved a good partial response with normalization of
spleen size and a complete blood count (CBC). The response
lasted 10 months, when relapse occurred, with splenomegaly
and bicytopenia (anemia and thrombocytopenia). The patient
was again transfusion-dependent, under treatment with H1
and H2 receptor blockers.
Discussion
Clinical manifestations of SM are very heterogeneous,
ranging from indolent to aggressive course with multisystem
involvement and short survival. Systemic mastocytosis can
coexist with other primary hematological disorders, such as
myelodysplastic syndrome, myeloproliferative disorder or
malignant lymphoma 
5.
Bone marrow biopsy in patients with SM often indi-
cates an increase in mast cells. Mast cells typically infiltrate
bone marrow and consequently affect peripheral blood. Be-
fore bone marrow sampling, the pathologist must be in-
formed about the possible diagnosis. A typical mast cell has
a spindle – shaped nucleus and fine eosinophilic granules,
and characteristic immunophenotype features (tryptase+,
CD117+). The spleen, liver and gastrointestinal tract are also
frequently involved 
6. In the presented patient cutaneus form
of mastocytosis preceded systemic mastocytosis. The disease
progressed, and aggressive course with multisystem in-
volvement was developed. Bone marrow biopsy showed
marked mast cell infiltration with specific immunophenotype
(CD117+, CD68+), and bone marrow fibrosis grade II was
found (Figure 2).
Fig. 1 – Skin lesions (urticaria pigmentosa) on the leg of the
patient
a) b)
Fig. 2 Bone marrow trephine biopsy speciments obtained in the 41-year-old patient with systemic mastocytosis
a) moderate fibrosis Gr II (Paraffin-embedded, HE ×100); b) spindle shaped mast-cells (paraffin-embedded, HE ×400)Strana 446 VOJNOSANITETSKI PREGLED Volumen 68, Broj 5
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Until now there has been no curative treatment for
SM. Patients with cutaneous or indolent systemic disease
are treated symptomatically, using histamine H1 and H2
receptor blockers and disodium cromoglycate. Aggressive
forms of SM are often associated with hematological disor-
der and are treated with cytoreductive therapy. Interpheron-
alfa and cytostatic drugs have been applied 
3, but relatively
little is known about the quality of responses to IFN-alpha.
Cladribine was effective in the patient with IFN-alpha re-
sistant SM 
7. Cladribine eliminates mast cell growth fac-
tors, as cytokines interleukin (IL) 3 and IL-4. The response
to cladribine in the presented patient was remarkably fast,
after the first cycle of cladribine, the histamine-related
symptoms vanished, and after a sixth cycle regression of
splenomegaly and pancytopenia were observed. The drug
was well tolerated, with no side effects. After a 10-month
good response the patient developed relapse. Positive effect
of cladribine treatment in 10 patients with systemic masto-
cytosis was published by Kluin-Nelemans et al. 
8, but a
complete remission was not achieved. Most patients treated
with cladribine showed a rapid decrease of mast cell infil-
tration and very good clinical response, as we observed in
the presented patient. In aggressive form of SM first line
treatment with cladribine as single agent is effective, but
disease often relapse.
Molecules targeting mutant kit tyrosine kinase are po-
tential agents in treatment, and they are under investigation
in clinical trials 
9, 10.
Conclusio
Cladribine therapy was efficient in the patient with
systemic mastocytosis but the response was transient, so
there is the need to search for new therapeutic options and
more effective strategies in the treatment of patients with ag-
gressive mast cell disorders.
So far there has not been established the standard ther-
apy for SM, and treatment has to be adjusted to the needs of
the individual patient. Advances in understanding the mo-
lecular pathogenesis of systemic mastocytosis will lead to
development of new therapeutic options.
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